4-Nitroquinoline-1-Oxide

4-Nitroquinoline-1-Oxide

SCHEMBL105454

O=[N+]([O-])c1cc[n+]([O-])c2ccccc12

nearest known ligand 0.56

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.56
MITF O75030 1/20 0.56
KDM4E B2RXH2 1/20 0.54
NPC1 O15118 1/20 0.54
S1PR4 O95977 1/20 0.54
S1PR1 P21453 1/20 0.54
HTT P42858 1/20 0.54
RAB9A P51151 1/20 0.54
NPSR1 Q6W5P4 1/20 0.54
TDP1 Q9NUW8 2/20 0.50
ALDH1A1 P00352 4/20 0.48
CTSB P07858 4/20 0.46
TSHR P16473 1/20 0.40
GAA P10253 2/20 0.39
AR P10275 1/20 0.39
HSD17B10 Q99714 2/20 0.39
POLB P06746 1/20 0.39
HPRT1 P00492 1/20 0.39
CASP6 P55212 1/20 0.39
CYP3A4 P08684 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
4-Nitroquinoline-1-Oxide SCHEMBL21114410 1.00 MAPT (0.56) MAPTMITFKDM4ENPC1S1PR4
4-Nitroquinoline-1-Oxide SCHEMBL29367999 1.00 MAPT (0.56) MAPTMITFKDM4ENPC1S1PR4
4-Nitroquinoline-1-Oxide SCHEMBL140249 0.92 MAPT (0.51) MAPTMITFKDM4ENPC1S1PR4
SCHEMBL2796338 0.87 TDP1 (0.59) MAPTMITFKDM4ENPC1S1PR4
4-Nitroquinoline-1-Oxide SCHEMBL9510491 0.82 MAPT (0.46) MAPTMITFKDM4ENPC1S1PR4
SCHEMBL16704752 0.80 MAPT (0.53) MAPTMITFKDM4ENPC1S1PR4
SCHEMBL7464842 0.76 MAPT (0.48) MAPTMITFKDM4ENPC1S1PR4
SCHEMBL3341802 0.76 TSHR (0.49) MAPTMITFKDM4ENPC1S1PR4
SCHEMBL5803068 0.76 MAPT (0.43) MAPTMITFKDM4ENPC1S1PR4
SCHEMBL3342386 0.76 TSHR (0.49) MAPTMITFKDM4ENPC1S1PR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1995 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260139331-A1 HIGH-THROUGHPUT METHODS FOR ISOLATING AND CHARACTERIZING AMMONIUM-EXCRETING MUTANT LIBRARIES GENERATED BY CHEMICAL MUTAGENESIS PIVOT BIO INC (US) 2026-05-21 US claimed
EP-4496889-A1 METHOD FOR DETECTING THE MUTAGENIC CHARACTER OF CHEMICAL COMPOUNDS Genevolution (FR) 2025-01-29 EP claimed
US-20240271119-A1 METHODS OF PERIPLASMIC PHAGE-ASSISTED CONTINUOUS EVOLUTION THE BROAD INSTITUTE, INC. (US) 2024-08-15 US claimed
EP-4377455-A1 METHODS OF PERIPLASMIC PHAGE-ASSISTED CONTINUOUS EVOLUTION The Broad Institute Inc. (US) 2024-06-05 EP claimed
EP-4376823-A1 COMPOUNDS INHIBITING THE SYNERGISTIC CARSINOGENIC EFFECT OF HEAVY METALS IN THE PRESENCE OF OTHER CARCINOGENS FOR USE IN THE TREATMENT OF CANCER Cancer Research And Biotechnology Ag (CH) 2024-06-05 EP claimed
US-20240174860-A1 HIGH OLEIC OIL COMPOSITIONS AND USES THEREOF CHECKERSPOT, INC. 2024-05-30 US claimed
CN-117886916-A N227 locus glycosylation of SBSPON and application thereof in bladder cancer drug resistance 深圳市第二人民医院(深圳市转化医学研究院) 2024-04-16 CN claimed
CN-117169522-A Mass spectrum positive ion mode metabonomics biomarker for peri-implant inflammation and application thereof 暨南大学附属第一医院(广州华侨医院) 2023-12-05 CN claimed
CN-117025513-A Preparation method of esophageal organoid cancerous tissue 上海市东方医院(同济大学附属东方医院) 2023-11-10 CN claimed
WO-2023180209-A1 METHOD FOR DETECTING THE MUTAGENIC CHARACTER OF CHEMICAL COMPOUNDS GENEVOLUTION (FR) 2023-09-28 WO claimed
EP-0576622-B1 LITHOGRAPHIC PRINTING PLATES EASTMAN KODAK CO (US) 1997-11-05 EP claimed
EP-0576622-A1 LITHOGRAPHIC PRINTING PLATES EASTMAN KODAK COMPANY (US) 1994-01-05 EP claimed
WO-1992017821-A1 LITHOGRAPHIC PRINTING PLATES EASTMAN KODAK COMPANY (US) 1992-10-15 WO claimed
US-5141842-A Negative working lithography printing plates EASTMAN KODAK COMPANY (US) 1992-08-25 US claimed
US-5141839-A LITHOGRAPHIC PRINTING PLATES HAVING A RADIATION-SENSITIVE LAYER COMPRISING A PHOTOCROSSLINKABLE POLYMER, A LEUCO DYE, A PHOTOOXIDANT AND A HETEROAROMATIC AMINE N-OXIDE EASTMAN KODAK COMPANY (US) 1992-08-25 US claimed
US-5100768-A Photoresists for integrated circuits, polyvinyl phenol and nitrogen containing heterocycle KABUSHIKI KAISHA TOSHIBA (JP) 1992-03-31 US claimed
EP-0449820-A1 RADIATION/MICROBE BIOASSAY TECHNICAL ASSESSMENT SYSTEMS, INC. (US) 1991-10-09 EP claimed
EP-0397474-A2 Photosensitive composition KABUSHIKI KAISHA TOSHIBA (JP) 1990-11-14 EP claimed
WO-1989010549-A2 RADIATION/MICROBE BIOASSAY TECHNICAL ASSESSMENT SYSTEMS, INC. (US) 1989-11-02 WO claimed
US-4568628-A Water developable diazo printing plate composition with quaternary nitrogen stabilizer POLYCHROME CORPORATION (US) 1986-02-04 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260139331-A1 HIGH-THROUGHPUT METHODS FOR ISOLATING AND CHARACTERIZING AMMONIUM-EXCRETING MUTANT LIBRARIES GENERATED BY CHEMICAL MUTAGENESIS GLUL, SPOUT1, QPCTL MAPT 3334/4885MITF 1565/4885KDM4E 1445/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.